{"id":"W4410821487","doi":"10.1200/jco.2025.43.16_suppl.4505","title":"Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Ipilimumab; Sunitinib; Nivolumab; Renal cell carcinoma; Internal medicine; Oncology; Phases of clinical research; Urology; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002224228,0.0008916958,0.001544663,0.0003216861,0.000278968,0.001173954,0.0006683526,0.0008551099,0.003426608],"category_scores_gemma":[0.001385969,0.0002850814,0.002444485,0.0003483192,0.0003393393,0.0005751084,0.0003208918,0.001789519,0.0004942168],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001062245,"about_ca_system_score_gemma":0.001057187,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001294104,"about_ca_topic_score_gemma":0.004445574,"domain_scores_codex":[0.9994916,0.0003145041,0.00002307134,0.00005970518,0.00004266607,0.0000683784],"domain_scores_gemma":[0.9993074,0.0001753792,0.0002058812,0.00004483222,0.0000334347,0.0002330431],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9251501,0.00389506,0.006392167,0.001131572,0.005178413,0.00008132201,0.00007728943,0.002376852,0.003641701,0.000182378,0.004986908,0.04690628],"study_design_scores_gemma":[0.8521903,0.1001214,0.03054559,0.0001544134,0.006757782,0.0003130236,0.00006200353,0.003522382,0.001695654,0.0005921659,0.00399599,0.00004944625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9829192,0.009721351,0.0004010673,0.0007163718,0.0002046486,0.0008707927,0.002282444,0.0001277696,0.002756312],"genre_scores_gemma":[0.9919522,0.002121822,0.0005622182,0.0006569537,0.0001476697,0.0006242906,0.002422176,0.00002421267,0.001488404],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003426608,"threshold_uncertainty_score":0.01176298,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1693839192076143,"score_gpt":0.4654664655370909,"score_spread":0.2960825463294766,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}